CION Ameerpet
Types & Staging · Reviewed by CION Oncologists · NABH Accredited
Uterine Carcinosarcoma — Formerly Called MMMT
This is an uncommon and aggressive cancer, and there is no version of that sentence worth softening. What has changed, and what matters practically, is how it is understood. Carcinosarcoma contains two kinds of tissue and was for decades classified and treated as a sarcoma under the name MMMT. Molecular work established that it actually begins as a carcinoma which then takes on sarcoma-like features — so it is now classified, and more importantly treated, as a high-risk carcinoma. If you have been reading older material that describes it as a uterine sarcoma, that is why the treatment being offered may not match what you found.
- It is a carcinoma, not a sarcoma — a reclassification that changed treatment
- MMMT is the old name — and still appears on many reports
- Aggressive, and stage still matters — as it does with every type
- Chemotherapy is central here — not an optional addition
17+
Cancer Specialists
on Panel
on Panel
35+
Centres
Across India
Across India
15,000+
Patients
Treated
Treated
4.8★
Google Rating
(800+ reviews)
(800+ reviews)
What This Diagnosis Involves
Set out directly. Each line explains something about the treatment that follows.
| Feature | What it means |
|---|---|
| Two tissue types, one origin | The tumour contains both carcinoma and sarcoma-like tissue. Both arise from the same original carcinoma, which is why it is treated as a carcinoma rather than as a sarcoma. See uterine sarcoma. |
| Also called MMMT | Malignant mixed Müllerian tumour — the older name, still appearing on many pathology reports. The same diagnosis, and the terminology on your report tells you nothing about how current your care is. |
| Aggressive behaviour | A marked tendency to invade deeply into the uterine wall, to enter lymphovascular spaces, to involve lymph nodes, and to spread within the abdomen. A substantial proportion of women have disease beyond the uterus when it is found. |
| Usually presents with bleeding | Most often postmenopausal bleeding, sometimes with a rapidly enlarging uterus or a mass visible at the cervix. Bleeding remains the symptom that brings women in, as with other endometrial cancers. |
| Comprehensive staging surgery | Hysterectomy with removal of tubes and ovaries, peritoneal washings, systematic node assessment and omental assessment — reflecting the spread pattern. See lymph nodes. |
| Chemotherapy as standard | Systemic treatment is central rather than an addition, using regimens for high-risk epithelial endometrial carcinoma rather than sarcoma regimens. See chemotherapy. |
| Frequently p53-abnormal | Most fall into this molecular group. Testing is still done, because a mismatch repair deficient tumour has systemic options that a p53-abnormal one does not. See molecular classification. |
Stage still matters here, as it does everywhere. Carcinosarcoma confined to the uterus and completely removed is a different situation from disease that has spread. When you look for information about outcomes, look for your stage rather than for the type in general.
Did You Know? For most of the twentieth century carcinosarcoma was grouped with the uterine sarcomas, because under the microscope it plainly contains sarcoma-like tissue. Molecular analysis then showed that both components share a single clonal origin in the carcinoma — the sarcoma-like part is a transformation of the same tumour, not a separate one. That finding had a direct clinical consequence: treatment moved from sarcoma chemotherapy regimens to the regimens used for high-risk epithelial endometrial carcinoma. It is one of the clearer examples of laboratory reclassification changing what happens in clinic, and it is why material published some years ago can be misleading about this diagnosis. Sources: WHO Classification of Tumours — Female Genital Tumours; NCCN Clinical Practice Guidelines in Oncology — Uterine Neoplasms; ESGO–ESTRO–ESP guidelines for the management of patients with endometrial carcinoma.
12+ Centres in Hyderabad · Pick yours
CION cancer care is closer than you think.
We're never more than 30 minutes away. Same panel of specialists at every centre. Same tumour board reviews. Same NCCN protocols. Pick the closest one and call directly — or let us pick for you.
CION Ameerpet
CION Kukatpally
CION L.B. Nagar
CION Tolichowki
CION Masab Tank
CION Banjara Hills
CION Kompally
CION Balanagar
CION Siddipet
CION Sangareddy
Not sure which centre fits best? Tell us where you are — we'll suggest the closest one with the right specialists.
Help me pick the right centre
Beyond Hyderabad
35+ centres across Telangana & Andhra Pradesh
Travelling for treatment? We may have a centre right where you are.
Telangana
Andhra Pradesh
Don't see your city? Call 18002028726 — we'll find your nearest CION partner centre.
Why the Reclassification Matters to You
Not a technicality — it changed what is given.
- The chemotherapy is different. Sarcoma regimens and carcinoma regimens are not the same, and the evidence now supports treating carcinosarcoma with the latter. If you have read that this is treated as a sarcoma, that reflects older practice.
- Staging follows carcinoma principles. The FIGO staging system for endometrial carcinoma applies, rather than sarcoma staging. This affects how your stage is described and how it should be interpreted. See FIGO staging.
- Molecular classification applies. Because it is a carcinoma, mismatch repair and p53 testing are relevant and are performed, which they would not routinely be for a true sarcoma. This can open systemic options in advanced or recurrent disease.
- The surgical approach reflects peritoneal spread. Washings and omental assessment are included because this tumour disseminates within the abdomen, in a pattern more like serous carcinoma than like a sarcoma. See serous carcinoma.
- Older information online is genuinely misleading. Material written before the reclassification describes different treatment and different framing. Where what you read does not match what you are being offered, this is frequently the explanation — and it is worth asking rather than assuming.
Want Your Plan Explained Against Current Practice?
Including why it may differ from material you have found describing this as a sarcoma.
Meet the Specialists
17+ senior cancer specialists. One panel for your case.
Trained at AIIMS, Tata Memorial, and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them — together.
Medical Oncologist
Medical Oncologist
Dr. C. Raghavendra Reddy
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
Medical Oncologist
Dr. Bharati Devi Gorantla
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
Medical Oncologist
Dr. Owais Mohammed
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
Medical Oncologist
Medical Oncologist
Surgical Oncologist
Dr. Muralidhar Muddusetty
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
Surgical Oncologist
Surgical Oncologist
Surgical Oncologist
Dr. Vinay Mamidala
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
Surgical Oncologist
Radiation Oncologist
Radiation Oncologist
Radiation Oncologist
Hematologist
Interventional Radiologist
Dr. Mohammed Imran
Surgical Oncologist
Dr. Vajja Sandeep Kumar
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Surgical Oncologist
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationBook an appointment with our specialist
Share your name and number — we'll call you back within 30 minutes to schedule your consultation.
Old Material Calls This a Sarcoma
It is treated as a high-risk carcinoma now — which is why your plan may not match what you read.
What to Ask For With This Diagnosis
Five things that matter more here than with the common type.
Treatment at a centre that sees these
Carcinosarcoma is uncommon, the staging surgery is more extensive than a standard hysterectomy, and the systemic treatment is specific. Ask how many the unit treats and whether a gynaecological oncologist is performing the surgery. This matters more for rare aggressive subtypes than for anything else on this site. See choosing a centre.
Confirmation that current protocols are being used
A reasonable and specific question: is the chemotherapy planned the regimen used for high-risk endometrial carcinoma, reflecting the reclassification? Asking it directly is not a challenge to your team; it is the kind of question a well-informed patient asks and a good oncologist welcomes.
Full molecular testing
Most of these tumours are p53-abnormal, and the minority that are mismatch repair deficient have systemic treatment options that would otherwise not be considered, particularly if the disease is advanced or returns. It should be done rather than assumed.
A specialist pathology review
Carcinosarcoma is diagnostically demanding and is distinguished from other mixed tumours and from high-grade carcinomas with unusual features. Review by a pathologist reporting gynaecological cases regularly is worth requesting before treatment begins.
A frank conversation about the plan
Ask what the intent of treatment is, what the sequence will be, and what the alternatives were. With an aggressive diagnosis, clarity is more useful than optimism, and a doctor who gives you a straight answer is doing you a service. See second opinion.
Want a Second Opinion Before Treatment Starts?
Slides reviewed, molecular testing completed, and your case taken to our tumour board. The opinion is free.
Holding This in Proportion
This page has not softened anything. These things are equally true.
- Treatment is active and it is worth having. Comprehensive surgery followed by chemotherapy, frequently with radiotherapy, is a demanding plan given with real intent. It is not a formality.
- Stage remains the dominant factor. Disease confined to the uterus and completely removed carries a materially different outlook from disease found to have spread. Your situation is your stage, not the type in the abstract.
- Complete surgical removal matters a great deal. Which is one of the strongest arguments for having the operation done by a team that performs comprehensive staging surgery routinely.
- Molecular testing has changed advanced disease. Mismatch repair status determines access to classes of systemic treatment that did not exist a decade ago, and it applies here because this is a carcinoma. See advanced disease treatment.
- Support is part of treatment, not separate from it. An aggressive diagnosis is hard to carry, and psychological support, symptom control and nutrition all affect how well treatment is tolerated. Ask for them rather than waiting to be offered. See coping with a diagnosis.
Why This Diagnosis Belongs With a Specialist Team
Uncommon, aggressive, and recently reclassified — three reasons the details of the plan matter.
Tumour board for every diagnosis
Slides reviewed, not just the summary line
MMR / MSI testing as standard
Sentinel node mapping where it fits
Psycho-oncology and nutrition on the team
Second opinions welcomed, not resented
Take The Next Step
Ask Whether Current Protocols Are Being Used
A specific, fair question — and one a good oncologist will welcome rather than resent.
Real Stories. Real Voices.
15,000+ patients chose CION. Hear from them directly.
These aren't paid endorsements or written reviews. These are video testimonials from real patients and families — recorded on their own phones, in their own words. Pick any one. Watch it. Then decide.
4.8★800+ Google reviews
50+video testimonials
15,000+patients treated
Read all 800+ reviews on Google
Start Your Story. Book Free Consultation.
Common questions
Uterine Carcinosarcoma — Frequently Asked Questions
What is uterine carcinosarcoma, and what is MMMT?
They are the same thing. MMMT stands for malignant mixed Müllerian tumour, the older name, which still appears on many pathology reports. It is an uncommon and aggressive uterine cancer containing two kinds of malignant tissue — carcinoma and sarcoma-like tissue. What changed the understanding of it was molecular work showing that both components share a single clonal origin in the carcinoma: the sarcoma-like part is a transformation of the same tumour rather than a separate one. It is therefore now classified and treated as a high-risk carcinoma rather than as a sarcoma.
Why does it matter whether it is called a carcinoma or a sarcoma?
Because it determines the treatment. Sarcoma chemotherapy regimens and carcinoma regimens are different, and the evidence now supports treating carcinosarcoma with the regimens used for high-risk epithelial endometrial cancer. The reclassification also means the FIGO staging system for endometrial carcinoma applies, and that molecular classification with mismatch repair and p53 testing is relevant — which would not routinely be the case for a true sarcoma, and which can open systemic treatment options in advanced or recurrent disease. This is a clear example of laboratory reclassification changing what happens in clinic.
I read online that this is treated as a uterine sarcoma. Is my treatment wrong?
Almost certainly not — what you read is probably out of date. Material published before the reclassification describes carcinosarcoma as a uterine sarcoma and describes sarcoma treatment accordingly, and a good deal of that material is still online. Current practice treats it as a high-risk carcinoma. If your plan does not match what you have read, this is very often the explanation. It is nevertheless a perfectly reasonable question to put to your oncologist directly: ask whether the chemotherapy planned is the regimen used for high-risk endometrial carcinoma. A good doctor will welcome the question.
How serious is this diagnosis?
It is among the more serious diagnoses in this group, and you deserve that stated plainly. Carcinosarcoma behaves aggressively, with a marked tendency to invade deeply, involve lymph nodes and spread within the abdomen, and a substantial proportion of women have disease beyond the uterus when it is found. Alongside that, stage remains the dominant factor: disease confined to the uterus and completely removed is a materially different situation from disease that has spread. Treatment — comprehensive surgery followed by chemotherapy, frequently with radiotherapy — is active and is given with real intent.
Does it matter where I have treatment?
More here than for almost anything else on this site. Carcinosarcoma is uncommon, so experience matters; the staging surgery is more extensive than a standard hysterectomy and includes peritoneal washings, systematic lymph node assessment and omental assessment; complete surgical removal has a significant bearing on outcome; and the systemic treatment is specific to current understanding of the tumour. Ask how many of these the unit treats each year, whether a gynaecological oncologist will perform the surgery, and whether your case will be discussed by a full multidisciplinary board before the plan is finalised.
Medical disclaimer: This page provides general information about uterine carcinosarcoma, reviewed by a CION oncologist. It is not a substitute for individual medical advice. Prognosis and treatment depend on stage, completeness of surgery, molecular findings and individual circumstances. Because this tumour is uncommon and has been reclassified in recent years, specialist gynaecological pathology review and multidisciplinary planning are recommended.